Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis

PURPOSE: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can lead to GI toxicity, termed immune-mediated diarrhea and colitis (IMDC). Standardization of IMDC management and early GI consultation is imperative to control symptoms and prevent delays in cancer care. Therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Saji, Alice, Chopra, Maneera, Jacob, Jake, Altan, Mehmet, Alhalabi, Omar, Shah, Amishi Yogesh, Qiao, Wei, Wang, Yinghong, Thomas, Anusha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803881/
https://www.ncbi.nlm.nih.gov/pubmed/36585982
http://dx.doi.org/10.1007/s00432-022-04504-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803881/
https://www.ncbi.nlm.nih.gov/pubmed/36585982
http://dx.doi.org/10.1007/s00432-022-04504-1

Ejemplares similares